Avian flu special: Is this our best shot?

Check, Erika
May 2005
Nature;5/26/2005, Vol. 435 Issue 7041, p404
Academic Journal
Considers issues hampering efforts to develop a vaccine against pandemic flu. Differences between a pandemic strain that has crossed over from birds and common flu; Problems encountered in clinical trials of flu vaccines; Funding of flu vaccine development.


Related Articles

  • New type of flu vaccine is quicker to produce.  // Modern Healthcare;11/26/2012, Vol. 42 Issue 48, p4 

    The article announces the approval of a new seasonal influenza vaccine called FluceIvax produced by Novartis Vaccines and Diagnostics by the U.S. Food and Drug Administration (FDA).

  • MedImmune: CAIV-T results not to be sneezed at.  // PharmaWatch: Biotechnology;Jun2006, Vol. 5 Issue 6, p7 

    The article reports on the results of the phase iII clinical trial of CAIV-T, an intranasal influenza vaccine from U.S.-based MedImmune. The drug has shown better efficacy than regular flu vaccine injections in young children in a late-stage study. CAIV-T nasal vaccine was 55 percent more...

  • H1N1 Pandemic Vaccine Safety: Results from Clinical Trials.  // Immunization Newsletter;2010, Vol. 32 Issue 2, p5 

    The article reports the results of the three clinical trials for the safety of H1N1 pandemic vaccines in China including the moderate and limited adverse events, incidence of systemic reactions, and incidence of local reactions.

  • Pediatric trials needed for pandemic influenza vaccine. Blazek, Nicole // Infectious Diseases in Children;Apr2009, Vol. 22 Issue 4, p23 

    The article emphasizes the need to conduct clinical trials for pediatric pandemic influenza vaccine.

  • Flu vaccine grown in insect cells.  // Wellness Options;2007, Issue 33, p13 

    This article reports on a trial of vaccines created in insect cells. Usually vaccines are produced in embryonated hen's eggs but the need for a more rapid vaccine growing method led scientists to try insect cells as the growth site. Once the vaccine was produced, it was tried out on a healthy...

  • Sanofi Pasteur and BD Team Up to Produce Microneedle Vaccines. Chiarello-Ebner, Kaylynn // Pharmaceutical Technology;Feb2006, Vol. 30 Issue 2, p18 

    The article reports on that Sanofi Pasteur, a manufacturer of vaccines, will collaborate with BD Pharmaceutical Systems to produce microneedle vaccines with patented Micro-Delivery System. Alexandre Conroy, president of BD's Medical-Pharmaceutical, said that the Micro-Delivery System will...

  • Development of universal influenza vaccines based on influenza virus M and NP genes. Zheng, M.; Luo, J.; Chen, Z. // Infection;Apr2014, Vol. 42 Issue 2, p251 

    Purpose: Vaccination is the safest and most effective measure against influenza virus infections. However, traditional influenza vaccines cannot respond effectively to an unforeseen epidemic or pandemic caused by a virus with antigenic drifts or antigenic shifts. Therefore, developing a...

  • The Fog of Research: Influenza Vaccine Trials during the 1918–19 Pandemic. EYLER, JOHN M. // Journal of the History of Medicine & Allied Sciences;Oct2009, Vol. 64 Issue 4, p401 

    Bacterial vaccines of various sorts were widely used for both preventive and therapeutic purposes during the great influenza pandemic of 1918–19. Some were derived exclusively from the Pfeiffer's bacillus, the presumed cause of influenza, while others contained one or more other organisms...

  • Hib Vaccine Efficacy Trials Continue; Data Needed About Use in Younger Children. Marwick, Charles // JAMA: Journal of the American Medical Association;4/14/89, Vol. 261 Issue 14, p2015 

    Reports on ongoing efficacy trials for the Haemophilus influenza type b (Hib) vaccination for children. Trials to study the efficacy of more potent versions of Hib vaccines; Dubbing of the vaccines 'conjugate vaccines'; Studies among infants in Alaska and Finland.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics